Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs

Although T cells expressing CD19-specific chimeric antigen receptors (CARs) are a promising new therapy for B-cell malignancies, objective responses are observed at lower frequencies in patients with lymphoma than in those with acute B-cell leukemia. We postulated that the tumor microenvironment sup...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Blood
Prif Awduron: Ninomiya, Soranobu, Narala, Neeharika, Huye, Leslie, Yagyu, Shigeki, Savoldo, Barbara, Dotti, Gianpietro, Heslop, Helen E., Brenner, Malcolm K., Rooney, Cliona M., Ramos, Carlos A.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society of Hematology 2015
Pynciau:
Immunobiology
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4473118/
https://ncbi.nlm.nih.gov/pubmed/25940712
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-01-621474
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg